Literature DB >> 8199108

Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases.

A D Paridaens1, D C Minassian, A C McCartney, J L Hungerford.   

Abstract

A series of 256 consecutive cases of invasive primary conjunctival malignant melanomas was examined to identify clinical and histopathological prognostic factors. The follow up period varied between 0.3 and 45.9 years (mean 9 years, median 6.3 years). The 5 year survival rate was estimated at 82.9%, the 10 year survival rate at 69.3%. Multiple regression analysis with the Cox proportional hazards model was used to assess sex, age, and a number of baseline features of conjunctival malignant melanoma as possible prognostic factors influencing melanoma related mortality. In assessing each potential prognostic factor, the effects of all other factors were taken into account in the modelling process. Tumours in unfavourable locations--that is, those involving the palpebral conjunctiva, fornices, plica, caruncle, and lid margins, were associated with 2.2 times higher mortality compared with (epi)bulbar melanomas. Patients with mixed cell type tumours had about three times higher mortality compared with those with pure spindle cell melanomas, and histological evidence of lymphatic invasion by tumour cells was also a prognostic feature, carrying a fourfold increase in the death rate. Multifocal tumours were associated with a fivefold increase in mortality among those with tumours in favourable (epi)bulbar locations, but were not prognostic in patients with melanomas in unfavourable sites. The death rate was significantly higher in those with initial tumour thickness of more than 4 mm, but only among patients with unfavourably located melanomas. Sex, age, and clinical origin of the tumour (primary acquired melanosis, pre-existing naevus, or de novo) were not useful prognostic indicators in this study.

Entities:  

Mesh:

Year:  1994        PMID: 8199108      PMCID: PMC504757          DOI: 10.1136/bjo.78.4.252

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  25 in total

1.  NAEVI AND MELANOMATA OF THE CONJUNCTIVA.

Authors:  B JAY
Journal:  Br J Ophthalmol       Date:  1965-04       Impact factor: 4.638

2.  Multifocal amelanotic conjunctival melanoma and acquired melanosis sine pigmento.

Authors:  A D Paridaens; A C McCartney; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1992-03       Impact factor: 4.638

3.  Epibulbar tumors.

Authors:  J E ASH
Journal:  Am J Ophthalmol       Date:  1950-08       Impact factor: 5.258

4.  Melanoma of the mucous membranes of the head and neck.

Authors:  J Conley; G T Pack
Journal:  Arch Otolaryngol       Date:  1974-05

5.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

6.  Recurrent malignant melanoma of the corneal stroma: a case of 'black cornea'.

Authors:  A D Paridaens; C M Kirkness; A Garner; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1992-07       Impact factor: 4.638

7.  Prognostic significance of the histological features of malignant melanoma.

Authors:  V J McGovern; H M Shaw; G W Milton; G A Farago
Journal:  Histopathology       Date:  1979-09       Impact factor: 5.087

8.  Malignant melanomas of the conjunctiva.

Authors:  V B Bernardino; M A Naidoff; W H Clark
Journal:  Am J Ophthalmol       Date:  1976-09       Impact factor: 5.258

9.  AgNOR counts in conjunctival malignant melanoma lack prognostic value.

Authors:  A D Paridaens; S Seregard; D Minassian; J L Hungerford; A C McCartney
Journal:  Br J Ophthalmol       Date:  1992-10       Impact factor: 4.638

10.  Oestrogen receptors in conjunctival malignant melanoma: immunocytochemical study using formalin fixed paraffin wax sections.

Authors:  D A Paridaens; R A Alexander; J L Hungerford; A C McCartney
Journal:  J Clin Pathol       Date:  1991-10       Impact factor: 3.411

View more
  42 in total

1.  Malignant melanoma of the conjunctiva with intraocular extension: a clinicopathological study of three cases.

Authors:  Teresa Sandinha; Heather Russell; Ewan Kemp; Fiona Roberts
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-29       Impact factor: 3.117

Review 2.  Updates in Ocular Surface Tumor Diagnostics.

Authors:  Afshan A Nanji; Carolina Mercado; Anat Galor; Sander Dubovy; Carol L Karp
Journal:  Int Ophthalmol Clin       Date:  2017

3.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

4.  Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection.

Authors:  Iku Kikuchi; Satoru Kase; Kan Ishijima; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

Review 5.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

6.  Conjunctival Melanoma during Pregnancy.

Authors:  Rana'a T Al-Jamal; Hardeep Singh Mudhar; Zanna Currie; Ian G Rennie; Sachin M Salvi
Journal:  Ocul Oncol Pathol       Date:  2016-11-08

7.  Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.

Authors:  P T Finger; G Czechonska; S Liarikos
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

Review 8.  Conjunctival melanoma and melanocytic intra-epithelial neoplasia.

Authors:  N Kenawy; S L Lake; S E Coupland; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

9.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

10.  Melanocytic Nevus of the Tarsal Conjunctiva.

Authors:  Bülent Yazıcı; Ayşe Dolar Bilge; Ayşe Yağcı; Faisal Naqadan; Filiz Altıntepe
Journal:  Balkan Med J       Date:  2016-07-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.